FDA approves Roche's Wilserdly (giredestrant) for ER-positive advanced breast cancer
FROM THE WIRE · FINANCE.YAHOO.COM
F. Hoffmann-La Roche Ltd Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial (evERA)1 In ESR1-mutatedpatients Wilserdly plus…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn FDA approval of a new oncology drug is positive for Roche, moving its shares without broad market impact.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA approved Wilserdly, a next-generation oral SERD.
- 02In the evERA trial it delayed progression or death by 62% with everolimus.
- 03The FDA is also reviewing the adjuvant setting with a decision expected by November 30.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Rogers Corporation123.46 USDMarket closedtoday -1.73%Positive Roche Holding AG414.20 CHFMarket closedtoday +0.53%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets